Sustained Effectiveness of an Advanced Hybrid Closed Loop System in a Cohort of Children and Adolescents With Type 1 Diabetes : A 1-Year Real-World Study
© 2024 by the American Diabetes Association..
OBJECTIVE: To investigate glucose metrics and identify potential predictors of the achievement of glycemic outcomes in children and adolescents during their first 12 months of MiniMed 780G use.
RESEARCH DESIGN AND METHODS: This multicenter, longitudinal, real-world study recruited 368 children and adolescents with type 1 diabetes (T1D) starting SmartGuard technology between June 2020 and June 2022. Ambulatory glucose profile data were collected during a 15-day run-in period (baseline), 2 weeks after automatic mode activation, and every 3 months. The influence of covariates on glycemic outcomes after 1 year of MiniMed 780G use was assessed.
RESULTS: After 15 days of automatic mode use, all glucose metrics improved compared with baseline (P < 0.001), except for time below range (P = 0.113) and coefficient of variation (P = 0.330). After 1 year, time in range (TIR) remained significantly higher than at baseline (75.3% vs. 62.8%, P < 0.001). The mean glycated hemoglobin (HbA1c) over the study duration was lower than the previous year (6.9 ± 0.6% vs. 7.4 ± 0.9%, P < 0.001). Time spent in tight range (70-140 mg/dL) was 51.1%, and the glycemia risk index was 27.6. Higher TIR levels were associated with a reduced number of automatic correction boluses (P < 0.001), fewer SmartGuard exits (P = 0.021), and longer time in automatic mode (P = 0.030). Individuals with baseline HbA1c >8% showed more relevant improvement in TIR levels (from 54.3 to 72.3%).
CONCLUSIONS: Our study highlights the sustained effectiveness of MiniMed 780G among youths with T1D. Findings suggest that even children and adolescents with low therapeutic engagement may benefit from SmartGuard technology.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - year:2024 |
|---|---|
| Enthalten in: |
Diabetes care - (2024) vom: 16. Apr. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Passanisi, Stefano [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
|---|
| Anmerkungen: |
Date Revised 16.04.2024 published: Print-Electronic Citation Status Publisher |
|---|
| doi: |
10.2337/dc23-2311 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM371153654 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM371153654 | ||
| 003 | DE-627 | ||
| 005 | 20240417233214.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240417s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2337/dc23-2311 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1378.xml |
| 035 | |a (DE-627)NLM371153654 | ||
| 035 | |a (NLM)38626260 | ||
| 035 | |a (PII)dc232311 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Passanisi, Stefano |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Sustained Effectiveness of an Advanced Hybrid Closed Loop System in a Cohort of Children and Adolescents With Type 1 Diabetes |b A 1-Year Real-World Study |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 16.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status Publisher | ||
| 520 | |a © 2024 by the American Diabetes Association. | ||
| 520 | |a OBJECTIVE: To investigate glucose metrics and identify potential predictors of the achievement of glycemic outcomes in children and adolescents during their first 12 months of MiniMed 780G use | ||
| 520 | |a RESEARCH DESIGN AND METHODS: This multicenter, longitudinal, real-world study recruited 368 children and adolescents with type 1 diabetes (T1D) starting SmartGuard technology between June 2020 and June 2022. Ambulatory glucose profile data were collected during a 15-day run-in period (baseline), 2 weeks after automatic mode activation, and every 3 months. The influence of covariates on glycemic outcomes after 1 year of MiniMed 780G use was assessed | ||
| 520 | |a RESULTS: After 15 days of automatic mode use, all glucose metrics improved compared with baseline (P < 0.001), except for time below range (P = 0.113) and coefficient of variation (P = 0.330). After 1 year, time in range (TIR) remained significantly higher than at baseline (75.3% vs. 62.8%, P < 0.001). The mean glycated hemoglobin (HbA1c) over the study duration was lower than the previous year (6.9 ± 0.6% vs. 7.4 ± 0.9%, P < 0.001). Time spent in tight range (70-140 mg/dL) was 51.1%, and the glycemia risk index was 27.6. Higher TIR levels were associated with a reduced number of automatic correction boluses (P < 0.001), fewer SmartGuard exits (P = 0.021), and longer time in automatic mode (P = 0.030). Individuals with baseline HbA1c >8% showed more relevant improvement in TIR levels (from 54.3 to 72.3%) | ||
| 520 | |a CONCLUSIONS: Our study highlights the sustained effectiveness of MiniMed 780G among youths with T1D. Findings suggest that even children and adolescents with low therapeutic engagement may benefit from SmartGuard technology | ||
| 650 | 4 | |a Journal Article | |
| 700 | 1 | |a Salzano, Giuseppina |e verfasserin |4 aut | |
| 700 | 1 | |a Bombaci, Bruno |e verfasserin |4 aut | |
| 700 | 1 | |a Minuto, Nicola |e verfasserin |4 aut | |
| 700 | 1 | |a Bassi, Marta |e verfasserin |4 aut | |
| 700 | 1 | |a Bonfanti, Riccardo |e verfasserin |4 aut | |
| 700 | 1 | |a Scialabba, Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Mozzillo, Enza |e verfasserin |4 aut | |
| 700 | 1 | |a Di Candia, Francesca |e verfasserin |4 aut | |
| 700 | 1 | |a Monti, Sara |e verfasserin |4 aut | |
| 700 | 1 | |a Graziani, Vanna |e verfasserin |4 aut | |
| 700 | 1 | |a Maffeis, Claudio |e verfasserin |4 aut | |
| 700 | 1 | |a Piona, Claudia Anita |e verfasserin |4 aut | |
| 700 | 1 | |a Arnaldi, Claudia |e verfasserin |4 aut | |
| 700 | 1 | |a Tosini, Davide |e verfasserin |4 aut | |
| 700 | 1 | |a Felappi, Barbara |e verfasserin |4 aut | |
| 700 | 1 | |a Roppolo, Rosalia |e verfasserin |4 aut | |
| 700 | 1 | |a Zanfardino, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Delvecchio, Maurizio |e verfasserin |4 aut | |
| 700 | 1 | |a Lo Presti, Donatella |e verfasserin |4 aut | |
| 700 | 1 | |a Calzi, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Ripoli, Carlo |e verfasserin |4 aut | |
| 700 | 1 | |a Franceschi, Roberto |e verfasserin |4 aut | |
| 700 | 1 | |a Reinstadler, Petra |e verfasserin |4 aut | |
| 700 | 1 | |a Rabbone, Ivana |e verfasserin |4 aut | |
| 700 | 1 | |a Maltoni, Giulio |e verfasserin |4 aut | |
| 700 | 1 | |a Alibrandi, Angela |e verfasserin |4 aut | |
| 700 | 1 | |a Zucchini, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Marigliano, Marco |e verfasserin |4 aut | |
| 700 | 1 | |a Lombardo, Fortunato |e verfasserin |4 aut | |
| 700 | 0 | |a ISPED Diabetes Study Group Collaborators |e verfasserin |4 aut | |
| 700 | 1 | |a Grosso, Caterina |e investigator |4 oth | |
| 700 | 1 | |a Cherubini, Valentino |e investigator |4 oth | |
| 700 | 1 | |a Tiberi, Valentina |e investigator |4 oth | |
| 700 | 1 | |a Piccinno, Elvira |e investigator |4 oth | |
| 700 | 1 | |a Zecchino, Clara |e investigator |4 oth | |
| 700 | 1 | |a Prandi, Elena |e investigator |4 oth | |
| 700 | 1 | |a Ricciardi, Maria Rossella |e investigator |4 oth | |
| 700 | 1 | |a Stamati, Filomena |e investigator |4 oth | |
| 700 | 1 | |a Costanza, Giuseppe |e investigator |4 oth | |
| 700 | 1 | |a Pezzino, Giulia |e investigator |4 oth | |
| 700 | 1 | |a Rosaria, De Marco |e investigator |4 oth | |
| 700 | 1 | |a Bratta, Anna |e investigator |4 oth | |
| 700 | 1 | |a Spacco, Giordano |e investigator |4 oth | |
| 700 | 1 | |a Rigamonti, Andrea |e investigator |4 oth | |
| 700 | 1 | |a Frontino, Giulio |e investigator |4 oth | |
| 700 | 1 | |a Predieri, Barbara |e investigator |4 oth | |
| 700 | 1 | |a Iafusco, Dario |e investigator |4 oth | |
| 700 | 1 | |a Rosanio, Francesco |e investigator |4 oth | |
| 700 | 1 | |a Pozzi, Erica |e investigator |4 oth | |
| 700 | 1 | |a Cardella, Francesca |e investigator |4 oth | |
| 700 | 1 | |a Dal Bo, Sara |e investigator |4 oth | |
| 700 | 1 | |a Riso, Chiara |e investigator |4 oth | |
| 773 | 0 | 8 | |i Enthalten in |t Diabetes care |d 1979 |g (2024) vom: 16. Apr. |w (DE-627)NLM00042983X |x 1935-5548 |7 nnns |
| 773 | 1 | 8 | |g year:2024 |g day:16 |g month:04 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.2337/dc23-2311 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |j 2024 |b 16 |c 04 | ||